| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.
|
J Pharmacol Exp Ther
|
2006
|
3.46
|
|
2
|
R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.
|
Cancer Res
|
2010
|
2.87
|
|
3
|
Discovering patterns to extract protein-protein interactions from full texts.
|
Bioinformatics
|
2004
|
2.42
|
|
4
|
A new algorithm for the evaluation of shotgun peptide sequencing in proteomics: support vector machine classification of peptide MS/MS spectra and SEQUEST scores.
|
J Proteome Res
|
2003
|
2.16
|
|
5
|
Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor.
|
Clin Immunol
|
2007
|
1.91
|
|
6
|
Multiple roles for the receptor tyrosine kinase axl in tumor formation.
|
Cancer Res
|
2005
|
1.87
|
|
7
|
Critical role of the ubiquitin ligase activity of UHRF1, a nuclear RING finger protein, in tumor cell growth.
|
Mol Biol Cell
|
2005
|
1.68
|
|
8
|
Identification of the Syk kinase inhibitor R112 by a human mast cell screen.
|
J Allergy Clin Immunol
|
2006
|
1.54
|
|
9
|
An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus.
|
Arthritis Rheum
|
2008
|
1.44
|
|
10
|
Activation of the PKB/AKT pathway by ICAM-2.
|
Immunity
|
2002
|
1.31
|
|
11
|
Substrate modification with lysine 63-linked ubiquitin chains through the UBC13-UEV1A ubiquitin-conjugating enzyme.
|
J Biol Chem
|
2007
|
1.25
|
|
12
|
Targeting Syk as a treatment for allergic and autoimmune disorders.
|
Expert Opin Investig Drugs
|
2004
|
1.20
|
|
13
|
The poxvirus p28 virulence factor is an E3 ubiquitin ligase.
|
J Biol Chem
|
2004
|
1.14
|
|
14
|
Identification and functional characterization of a novel human misshapen/Nck interacting kinase-related kinase, hMINK beta.
|
J Biol Chem
|
2004
|
1.12
|
|
15
|
Retrovirally delivered random cyclic Peptide libraries yield inhibitors of interleukin-4 signaling in human B cells.
|
J Biol Chem
|
2002
|
1.04
|
|
16
|
A novel E3 ubiquitin ligase TRAC-1 positively regulates T cell activation.
|
J Immunol
|
2005
|
1.04
|
|
17
|
Cell cycle regulatory E3 ubiquitin ligases as anticancer targets.
|
Drug Resist Updat
|
2002
|
0.99
|
|
18
|
AMPK activation through mitochondrial regulation results in increased substrate oxidation and improved metabolic parameters in models of diabetes.
|
PLoS One
|
2013
|
0.94
|
|
19
|
Drug discovery in the ubiquitin regulatory pathway.
|
Drug Discov Today
|
2003
|
0.94
|
|
20
|
High-throughput screening for inhibitors of the e3 ubiquitin ligase APC.
|
Methods Enzymol
|
2005
|
0.92
|
|
21
|
JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice.
|
J Immunol
|
2009
|
0.88
|
|
22
|
Use of MEDUSA-based data analysis and capillary HPLC-ion-trap mass spectrometry to examine complex immunoaffinity extracts of RBAp48.
|
J Proteome Res
|
2003
|
0.87
|
|
23
|
A novel role for p21-activated protein kinase 2 in T cell activation.
|
J Immunol
|
2004
|
0.87
|
|
24
|
Multiple functional categories of proteins identified in an in vitro cellular ubiquitin affinity extract using shotgun peptide sequencing.
|
J Proteome Res
|
2003
|
0.87
|
|
25
|
Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen.
|
J Cancer Res Clin Oncol
|
2010
|
0.86
|
|
26
|
The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseases.
|
Int J Hematol
|
2010
|
0.86
|
|
27
|
R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm.
|
Blood
|
2011
|
0.85
|
|
28
|
Cellular localization and antiproliferative effect of peptides discovered from a functional screen of a retrovirally delivered random peptide library.
|
Chem Biol
|
2003
|
0.85
|
|
29
|
A class of small molecules that inhibit TNFalpha-induced survival and death pathways via prevention of interactions between TNFalphaRI, TRADD, and RIP1.
|
Chem Biol
|
2007
|
0.84
|
|
30
|
Discovery and development of spleen tyrosine kinase (SYK) inhibitors.
|
J Med Chem
|
2012
|
0.82
|
|
31
|
Exercise performance and peripheral vascular insufficiency improve with AMPK activation in high-fat diet-fed mice.
|
Am J Physiol Heart Circ Physiol
|
2014
|
0.81
|
|
32
|
A homogeneous FRET assay system for multiubiquitin chain assembly and disassembly.
|
Methods Enzymol
|
2005
|
0.80
|
|
33
|
Discovery and characterization of substituted diphenyl heterocyclic compounds as potent and selective inhibitors of hepatitis C virus replication.
|
Antimicrob Agents Chemother
|
2008
|
0.80
|
|
34
|
Computational and experimental studies on human misshapen/NIK-related kinase MINK-1.
|
Curr Med Chem
|
2004
|
0.77
|
|
35
|
Gas phase dimerization of neuropeptide head activator analogs useful for the noncovalent constraint of peptides.
|
Biopolymers
|
2007
|
0.76
|
|
36
|
R-253 disrupts microtubule networks in multiple tumor cell lines.
|
Clin Cancer Res
|
2006
|
0.75
|
|
37
|
Global metabolite profiling of mice with high-fat diet-induced obesity chronically treated with AMPK activators R118 or metformin reveals tissue-selective alterations in metabolic pathways.
|
BMC Res Notes
|
2014
|
0.75
|
|
38
|
Cellular interacting proteins of functional screen-derived antiproliferative and cytotoxic peptides discovered using shotgun peptide sequencing.
|
Chem Biol
|
2003
|
0.75
|